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1. ABSTRACT 
Pancreatic cancer is a highly aggressive cancer with gemcitabine as its standard 
therapeutic basis. We previously established a role for HSP27 as a prognostic and 
predictive marker in pancreatic cancer: Tissue-microarray studies showed increased 
HSP27 expression in pancreatic cancer specimens to be associated with better patient 
survival, while HSP27 overexpression unexpectedly increased susceptibility 
specifically towards gemcitabine in a pancreatic cancer cell line model. Vice versa, 
HSP27 protein depletion in HSP27 high-expressing AsPC-1 cells caused increased 
gemcitabine resistance. Here, we investigate the underlying mechanisms of HSP27- 
mediated gemcitabine sensitivity in pancreatic cancer cells. Utilizing a pancreatic 
cancer cell model with stable HSP27 overexpression, cell cycle arrest and apoptosis 
induction were analyzed by flow cytometry, nuclear staining, immunoblotting and 
mitochondrial staining. Drug sensitivity studies were performed by proliferation 
assays. Hyperthermia was stimulated using mild heat-shock at 41.8 °C. Upon 
gemcitabine treatment, HSP27-overexpressing cells displayed an early S-phase arrest 
subsequently followed by a strongly increased sub-G1 fraction. Apoptosis was 
characterized by PARP-, CASPASE 3-, CASPASE 8-, CASPASE 9- and BIM- activa-
tion along with a mitochondrial membrane potential loss. It was reversible through 
chemical caspase inhibition. Importantly, heat shock-mediated HSP27 induction 
similarly increased gemcitabine sensitivity in a panel of pancreatic cancer cell lines. 
Finally, HSP27-overexpressing pancreatic cancer cells displayed an increased 
sensitivity also towards death receptor-targeting agents, suggesting additional 
pro-apoptotic functions of HSP27 along the extrinsic apoptosis pathway. Taken 
together, in contrast to the well-established anti-apoptotic properties of HSP27 in 
cancer, our study reveals novel pro-apoptotic functions of HSP27- mediated through 
both the intrinsic and the extrinsic apoptotic pathways- at least in pancreatic cancer 
cells. HSP27 could represent a predictive marker of therapeutic response towards 
specific drug classes in pancreatic cancer and provides a novel molecular rationale for 
current clinical trials applying the combination of gemcitabine with regional 
hyperthermia in pancreatic cancer patients.
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2. INTRODUCTION 
2.1 Pancreatic cancer  
2.1.1 Status Quo  
Since forty years ago the US President Nixon "declared" War on Cancer [1], there 
have been obvious triumphs, for instance, it has been recognized that cancer harbors 
six significant hallmarks, sustaining proliferative signaling, resisting cell death, 
inducing angiogenesis, enabling replicative immortality, activating invasion and 
metastasis, evading growth suppressors [2,3]. During the past two decades, 
remarkable improvements have been made in treating malignant tumors. However, 
the war towards pancreatic cancer seems to be one of the most difficult tasks with 
dismal success in decreasing the mortality of the patients. In 2012, a statistical report 
has illustrated that pancreatic cancer remains the fourth leading cause of cancer 
modality among both men and women in the United States and little improvements 
have been shown in survival over the past 30 years [4]. The clinical treatment failure 
is often attributed to the early metastatic growth, a high drug-resistance to standard 
therapy options and high rates of local recurrence [5,6]. Thus the development of new 
and efficacious treatments is urgently demanded.  
2.1.2 General principles for treating pancreatic cancer 
The current management of pancreatic cancer is mainly guided by tumor stage, 
comorbidities and performance status of the patients. Surgical resection and a 
6-month-course of adjuvant gemcitabine-based chemotherapy is the standard 
treatment for pancreatic cancer patients at an early stage [7]. In contrast, systemic 
palliative chemotherapy is applied for the patients with metastatic disease, while 
optimal treatment, with chemotherapy alone and/or chemoradiation, is still debated 
for patients with locally advanced disease but without evidence of metastasis [8]. 
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2.1.2.1 Surgery 
At present, surgical resection with negative margins (R0) is the only opportunity for 
cure [9]. Curative resection approaches contain pancreaticoduodenectomy, which is 
suitable for the majority of pancreatic cancer patients because of uncinate infiltration 
with the head and/or neck, and distal pancreatectomy for tumors which infiltrated the 
body and tail part [10]. However, as most patients have locally advanced or metastatic 
pancreatic cancer at the time of diagnosis, surgery is applicable in less than 20% [4]. 
2.1.2.2 Systemic chemotherapy: gemcitabine as the first-line regimen  
Single-agent gemcitabine (GEM) has been approved as the first line chemotherapy for 
locally advanced or metastatic nonresectable pancreatic cancer by the National 
Comprehensive Cancer Network (NCCN) practice guidelines since 1997 [11]. 
Although gemcitabine could improve the survival rate only a few months [12,13], it 
remains the standard therapeutic basis in most clinical settings for pancreatic cancer 
patients [14]. 
Until now, numerous chemotherapeutic agents including 5-FU, cisplatin, oxaliplatin, 
and capecitabine have been evaluated alone or in combination in clinical trials and 
some promising findings have been reported [8]. A recent combinational regimen 
using oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) 
significantly improved overall survival compared with gemcitabine and it was 
suggested that FOLFIRINOX might be an option for the patients with metastatic 
pancreatic cancer and good performance status [15]. Moreover, in patients with 
metastatic pancreatic cancer, nab-paclitaxel plus gemcitabine significantly improved 
overall survival, progression-free survival, and response rate, but rates of peripheral 
neuropathy and myelosuppression were increased [16].  
Additionally, with the great breakthroughs on molecularly targeted molecules in 
cancer and understandings on the biological properties of pancreatic cancer, novel 
targeted agents have been evaluated in pancreatic cancer [17,18]. Since earlier and 
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later studies on anti-estrogen receptor therapies such as tamoxifen failed to 
demonstrate any survival benefit for the treatment [19-21], recent studies are mainly 
focused on the genes overexpressed or mutated in pancreatic cancer such as epidermal 
growth factor receptor (EGFR), human epidermal growth factor receptor type 2 
(HER2) and vascular endothelial growth factor (VEGF), etc [22]. Molecular drugs 
including anti-HER1/EGFR inhibitor erlotinib, anti-VEGF antibody bevazicumab, 
anti-HER2 antibody trastuzumab, or multikinase inhibitors with antiangiogenic 
activity such as axitinib, sunitinib and sorafenib [23-28] have been tested in the 
clinical settings. Nevertheless, only erlotinib in combination with gemcitabine showed 
a minimal increase in median overall survival of about two weeks compared with 
gemcitabine plus placebo. In particular, a small subgroup of patients with more skin 
rash as a side effect of erlotinib treatment showed a significantly prolonged median 
survival of approximately 10 months [28].  
To date, only a few clinical trials have evaluated the use of second-line regimens after 
the failure of first-line gemcitabine therapy [7]. One randomized trial tested the 
combination of oxaliplatin and 5-FU versus best supportive care after failure of 
gemcitabine treatment and indicated a potentially benefit from the 5-FU and 
platinum-based combination regimen after gemcitabine-based monotherapy, with an 
increased survival of 4.82 months versus 2.3 months [7,29]. But definitive results 
from large randomized clinical trials about second-line chemotherapy are still needed 
[30]. 
2.1.3 Gemcitabine resistance 
Although gemcitabine remains the cornerstone of neoadjuvant and adjuvant 
chemotherapy in pancreatic cancer, the response rate is only 5.4% [11] and a 
progression-free survival interval imparts a range from 0.9 to 4.2 months [31]. 
Moreover, increasing reports have illustrated the dismal prognosis of pancreatic 
cancer is partly ascribable to the inherent or secondarily acquired resistance towards 
gemcitabine treatment [32,33].  
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2.1.3.1 Metabolism of gemcitabine 
Gemcitabine (2, 2-difluorodeoxycytidine; dFdC) is a nucleoside prodrug with a 
complex metabolism (Fig. 1). After entering across the plasma membrane through 
nucleoside transporters, gemcitabine is phosphorylated into gemcitabine 
monophosphate (dFdCMP) by deoxycytidine kinase (dCK) in a rate-limiting manner. 
Subsequently, dFdCMP is converted through nucleoside kinases to its active 
metabolites, the triphosphate- (dFdCTP) and diphosphate- (dFdCDP) nucleoside 
analogues [34]. dFdCTP confers its subsequent cytotoxicity through inhibition of 
DNA synthesis, while dFdCDP inhibits ribonucleotide reductase (RR), converting 
ribonucleosides to deoxyribonucleoside triphosphates (dNTPs), which is essential for 
DNA polymerisation and repair [35,36]. More than 90% of transported gemcitabine is 
inactivated by cytidine deaminase (CDA) into 2’-deoxy-2’, 2’-difluorouridine (dFdU). 
Additionally, phosphorylated gemcitabine is converted by cellular 5’-nucleotidase 
(5’-NT), and dFdCMP can also be inactivated by deoxycytidine monophosphate 
deaminase (DCTD) into 2’-deoxy-2’, 2’-difluorouridine monophosphate (dFdUMP) 
[37-39]. 
 
Figure 1. Metabolism of gemcitabine. (copied from Ueno et al 2007 [39]) 
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2.1.3.2 Strategies to improve gemcitabine resistance 
In the past decades, drug delivery, transport and metabolism of gemcitabine have been 
extensively studied [40] and various approaches have been developed to improve the 
sensitivity towards gemcitabine [41,42].  
Innovative drug delivery 
One of the most promising approaches for improving gemcitabine resistance is the use 
of innovative drug delivery devices [32,43]. Encouraging results have been achieved 
through the use of modified gemcitabine by liposomal encapsulation over the past 5 
years [44,45]. In addition, novel supramolecular vesicular aggregates (SVAs) [46], 
polymeric nanoparticles [47,48] and squalenoylation [49-51] are also interesting to be 
used for the administration of the nucleoside analog [52].  
Effective drug transport 
Another intriguing approach is to increase the expressions of effective nucleoside 
transporters [53-55]. Plasma nucleoside transporter proteins majorly comprise two 
functionally distinct groups, the sodium-independent hENTs (human equilibrative 
nucleoside transporters) and the sodium-dependent hCNTs (human concentrative 
nucleoside transporters) [56]. The former group encompasses two transproters, 
hENT1 and hENT2, whereas the latter includes three isoforms, hCNT1, hCNT2, 
hCNT3 [53]. Of interest, hCNT1, hCNT3 and hENT1 are found to be the major 
transporters responsible for gemcitabine uptake into cells [57-59]. Recent clinical 
studies have reported overexpression of the three transporters is correlated with a 
significantly improved outcome for pancreatic cancer patients treated with 
gemcitabine [58,60-62].  
Improved metabolism 
Activities of some metabolic enzymes during the activation of gemcitabine have been 
reported to represent one major mechanism for gemcitabine resistance [63]. 
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Modulation or genetic changes of these enzymes could improve therapeutic responses 
for pancreatic cancer. For example, mutation or deficiency of dCK has been 
considered to be one important mechanism for gemcitabine resistance [64,65]. In 
contrast, high expressions of the catabolic enzymes 5’-NT and CDA are also 
associated with cellular resistance to gemcitabine [66,67]. Moreover, gemcitabine 
resistance has been correlated with the overexpression of two RR subunits, RRM1 
[68,69] and RRM2 [70,71].  
2.1.4 Biomarkers for gemcitabine sensitivity in pancreatic cancer 
In the past ten years, several potential predictive biomarkers alone or in combination 
have been mentioned for gemcitabine-based treatments in pancreatic cancer. It was 
reported that CA19-9 might serve as an indicator of response to gemcitabine-based 
chemotherapy in advanced pancreatic cancer [72,73]. Also, the expression levels of 
hENT1 were suggested for stratification of patients to chemotherapy including 
gemcitabine [60]. Moreover, dCK [74], RR subunits (RRM1 [75] and RRM2 [63]), 
Notch3 [76], Hu protein antigen R (HuR) [77], microRNAs [78] were found to be 
useful in predicting gemcitabine sensitivity of patients with pancreatic cancer. 
However, none of these markers has yet proven sufficiently robust to achieve clinical 
implementation in the gemcitabine-based treatment of pancreatic cancer. 
2.1.5 Small summary 
Despite much effort in the past decades, pancreatic cancer remains to be one of the 
most difficult-to-treat diseases. Except for surgery and systemic chemotherapy using 
gemcitabine, few therapeutic options have yet led to a measurable improvement in 
outcome. Therefore, it will be crucial to identify promising predictive markers for 
individualized treatment approaches based on molecular tumor characteristics and/or 
prognostic factors to improve the response towards traditional treatments. Particularly, 
new biomarkers predicting response towards gemcitabine treatment are urgently 
needed [79].  
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2.2 Heat shock protein 27 
2.2.1 Heat shock proteins  
Heat shock proteins (HSPs) are a set of evolutionarily conserved proteins first 
discovered in 1962 by Ritossa [80]. In human, HSPs are classified into two groups 
according to their sizes: large molecular weight HSPs and small molecular weight 
HSPs. The former group includes HSP110, HSP90 (HSPC), HSP70 (HSPA) and 
HSP60 (HSPD), and the latter are small HSPs (15 to 30 kDa) including HSP27 
[81-83].  
Normally, HSPs function as molecular chaperones for a large panel of ‘client’ proteins 
and have strong cytoprotective properties through the maintenance of cellular 
homeostasis under various physiological and stress conditions, including heat [84] 
and oxidative stress [85,86]. As has been convincingly shown in the last decades, 
HSPs are implicated in the pathogenesis of many diseases, such as neurodegeneration, 
myopathies, cardiomyopathies, cataracts, inflammatory diseases, and cancer [87]. 
Recently, various HSPs such as HSP90, HSP70, HSP27 were shown to be 
constitutively overexpressed in a wide range of tumor malignancies and are associated 
with prognosis, carcinogenesis, tumor differentiation and drug resistance [88]. Many 
reports reported overexpression of HSPs in various tumor entities to be connected to 
the suppression of apoptosis, exerted likely by their cytoprotective origin as 
chaperones [82,89]. However, HSPs appear to also exhibit pro-apoptotic functions 
and conflicting data exist [90], which is particularly true for HSP27 [90]. 
2.2.2 Roles of HSP27 in cancer 
As one of the small HSPs, HSP27 possesses chaperone-like activity with preventing 
aggregation of misfolded proteins and has been implicated in proteasome-mediated 
protein degradation as well as in the modulation of cell death pathways [83,91-93]. 
Interestingly, HSP27 is found to be constitutively highly expressed in various tumor 
entities such as lung [94], gastric [95], prostate [96] and pancreatic cancers [97]. In 
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some tumor entities, this HSP27 overexpression appears to be associated with 
prognosis [98], tumor progression [90,99] or response to treatment [88,100-102]. 
Thus HSP27 has been suggested as a diagnostic, predictive and prognostic marker, 
implicating it as a potential therapeutic target molecule [88,103]. However, there are 
debates about the functional roles of HSP27 in cancer because conflicting findings 
have been reported [90]. Regarding HSP27 as prognostic marker, HSP27 
overexpression was associated with poor prognosis in osteosarcomas [104], gastric 
[105,106], liver [107], prostate [108,109] and rectal cancer [110], while it was 
associated with favorable prognosis in endometrial adenocarcinomas [111], 
esophageal cancer [112], neuroblastomas [113] and malignant fibrous histiocytoma 
[114]. Inconclusive or conflicting findings were reported in breast [115-117], ovarian 
[118,119], oral [120,121] and pancreatic cancer [122]. Regarding HSP27 as a 
predictive marker, its upregulation was associated with radioresistance [123] in 
nasopharyngeal carcinoma cells [102], while data were inconsistent in head and neck 
cancer [124,125]. In regard to chemosensitivity, increased HSP27 expression has been 
reported to be associated with chemoresistance in a variety of cancers [88]. However, 
high HSP27 expression was strongly associated with tumor response to neoadjuvant 
chemotherapy in esophageal adenocarcinomas [126]. 
2.2.2.1 HSP27-regulated apoptosis in cancer 
Previously, numerous reports indicated that HSP27 exerts predominantly 
anti-apoptotic effects in a variety of cancers [83], which is supported by its interaction 
with a plethora of apoptotic mediators. For example, HSP27 inhibits apoptosis 
through a caspase-dependent (intrinsic) pathway by binding to CASPASE 3 and 
CYTOCHROME C, preventing its interaction with APAF-1 and pro-CASPASE 9, and 
by inactivating BAX [127-130]. Furthermore, it has been reported that low expression 
of HSP27 induced apoptosis through a caspase-dependent pathway [128]. However, 
there are also conflicting findings about the roles of HSP27 in regard to apoptosis 
[131]. For instance, reports indicate that HSP27-dependent apoptosis was 
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caspase-independent [132,133].  
2.2.2.2 Paradoxical roles of HSP27 in pancreatic cancer 
As described above, the specific functional roles of HSP27 on the molecular level 
remain insufficiently understood and seem variable depending on tumor type or entity 
[88,134]. This applies particularly to the role of HSP27 as a prognostic marker in 
pancreatic cancer, for which on the one hand, HSP27 overexpression was associated 
with poor prognosis [135,136] and chemoresistance towards gemcitabine in some 
studies [137-140], while on the other hand, it was associated with good prognosis and 
increased sensitivity towards gemcitabine in others [122]. 
Similarly, the role of HSP27 as a predictive marker for gemcitabine sensitivity 
remains controversial [90,122,138]: In pancreatic cancer, HSP27 overexpression was 
shown to correlate with tumor aggressiveness and chemoresistance, indicating it as a 
potentially negative marker for gemcitabine response [97,135,136,138]. In contrast to 
those results, we have recently shown that high expression of HSP27 could serve as a 
positive prognostic marker in pancreatic cancer and that exogenous overexpression of 
HSP27 in pancreatic cancer cells conferred increased sensitivity to gemcitabine, 
indicating HSP27 as a potentially positive predictive marker for therapeutic response 
[122]. 
2.2.2.3 Roles of posttranslational modifications of HSP27 in cancer 
HSP27 is regulated through posttranslational modifications such as phosphorylation 
[141]. Phosphorylation of HSP27 is mediated by the p38 MAPK stress kinase 
pathway through various kinases, including MAPK-activated protein kinase-2 (MK2), 
MK3, MK5, protein kinase A (PKA), AKT/protein kinase B (PKB), Protein kinase C 
(PKC), Protein kinase D (PKD), cGMP-dependent protein kinase, Ribosomal protein 
S6 kinase II (p70RSK) and apoptosis signal-regulating kinase (ASK1) [142]. HSP27 is 
phosphorylated at three serine residues (Ser15, Ser78 and Ser82) [143]. This 
phosphorylation is a reversible process that regulates another posttranslational 
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modification of HSP27, the oligomerization of HSP27 [128]. This modification 
switches the formation of large oligomers to monomers or dimers. However, 
phosphorylation of HSP27 appears not to represent the only mechanism for regulating 
the HSP27 oligomerization including the formation of larger oligomers [128,144].  
As compared to the less-studied oligomerization of HSP27, HSP27 phosphorylation 
has been more frequently examined in various malignancies. Of interest, increased 
HSP27 phosphorylation was found in different types of tumors [145,146] and might 
be associated with drug resistance [147,148]. For example, elevated phosphorylation 
of HSP27 might inhibit apoptosis [132] and was therefore proposed as a potential 
therapeutic target [149]. In pancreatic cancer, phosphorylated HSP27 might be a 
predictive biomarker for the sensitivity towards gemcitabine [150].  
2.2.2.4 Other related signaling pathways 
In addition to its implication in apoptotic pathways, overexpressed HSP27 interacts 
with many other signaling pathways in cancer, such as ASK1/p38/JNK pathway [151]. 
However, debated reports exist [152,153].  
2.2.3 Small summary of HSP27 in cancer  
HSP27 is constitutively overexpressed in various tumor malignancies and its 
overexpression has been associated with prognosis, diagnosis and therapeutic 
response in some tumor entities. Thus HSP27 could serve as a biomarker in various 
tumor types. However, the specific molecular functions of HSP27 in cancer are 
insufficiently understood. In particular, the role of HSP27 as a predictive marker for 
gemcitabine response in pancreatic cancer remains controversial.  
2.3 Preceding own studies and deducted hypothesis 
Previously, in order to identify novel biomarkers for pancreatic cancer, our group used 
Tissue-microarray (TMA) studies to analyze 86 specimens from pancreatic cancer 
patients after surgery in the Klinikum Grosshadern of Ludwig-Maximilians 
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University in Munich in Germany. We found that HSP27 could serve as a prognostic 
biomarker in pancreatic cancer. To test its potential role as a predictive marker for 
therapeutic response, a cellular HSP27 overexpression model was generated in PL5 
pancreatic cancer cells. In this model, we were able to show that stably 
overexpressing HSP27 cell clones displayed drastically increased sensitivity 
specifically towards gemcitabine but not towards other agents commonly used for 
pancreatic cancer treatment [122].  
2.4 Aim of the work 
Pancreatic cancer is a highly aggressive cancer. Despite encouraging recent advances, 
gemcitabine remains the standard therapeutic basis in most clinical settings. Due to 
the common primary or acquired resistance of pancreatic cancer cells towards 
gemcitabine, predictive markers for chemotherapeutic response are urgently needed. 
In our previous publication, we demonstrated that HSP27 could serve as a predictive 
marker for gemcitabine response since HSP27 overexpression drastically increased 
gemcitabine sensitivity. Thus the aims of this thesis can be summarized as follows: 
1. To create a complementary cellular model system using RNA-interference 
technology to validate the results observed in the HSP27 overexpression 
model. 
2. To explore the mechanistic basis of the observed effects, particularly in 
regard to: 
a. Cell cycle modulation; 
b. Apoptosis; 
c. Others (the metabolism of gemcitabine; other related signaling 
pathways; postmodifications of HSP27; etc.)  
3. To analyze potential synergistic interactions between gemcitabine treatment 
and hyperthermia-induced HSP27 overexpression. 
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3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 General consumables  
Consumables Manufacturers 
Non-pyrogenic serological pipet 
(2, 5, 10, 25 ml)  
Sigma-Aldrich Chemie GmbH, Germany 
PCR soft tubes Fisher Scientific-Germany GmbH, Schwerte, 
Germany 
Polyallomer tubes for 
ultracentrifugation (5 mm×10 
mm) (#342630) 
Beckman Coulter GmbH, Krefeld, Germany 
Coverslip Thermo Scientific Gerhard Menzel, Braunschweig, 
Germany 
Cell Scraper 16cm Sarstedt, Germany 
Cuvettes Sarstedt 
Cover glass Fisher Scientific- Germany GmbH 
10cm cell culture dishes BD Biosciences, Heidelberg, Germany 
96-/12-/6-well plates BD Biosciences 
Cubic tubes (15, 50 ml) BD Biosciences 
Cryotubes Cryo.STM Greiner Bio-one GmbH, Germany 
Micro tubes (1.5 ml) Sarstedt 
Micro tubes (2 ml) Eppendorf Vertrieb Deutschland GmbH, 
Wesseling-Berzdorf, Germany 
General pipettes (1 ml, 200 µl, 
20 µl, 10 µl) 
Eppendorf Vertrieb Deutschland GmbH 
Glas Pasteur Pipettes BRAND GmbH, Wertheim, Germany 
Ranin pipettes/tips Mettler-Toledo, LLC, Columbus, USA 
Pipet tips VWR International GmbH, Darmstadt, Germany 
Gel Transfer filter paper Germany 
PVDF Membrane Zefa-Laborservice GmbH, Harthausen, Germany 
X-ray film for immunoblotting Fuji Film Europe GmbH, Düsseldorf, Germany 
PARAFILM® M Sigma-Aldrich Chemie GmbH 
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3.1.2 Reagents 
Reagents Manufacturers 
G418 (neomycin) Carl Roth GmbH, Karlsruhe, Germany 
Oligofectamine™ Reagent Invitrogen, Life Technologies GmbH, 
Darmstadt, Germany 
Lipofectamine™ 2000 Reagent Invitrogen 
Lipofectamine™ Reagent Invitrogen 
Polyethylenimine (PEI) a gift from Benjamin Hirschi 
(benjamin.hirschi@helmholtz-muenchen.de) 
Gemcitabine (Gemza) Lilly Deutschland GmbH, Bad Homburg, 
Germany 
SYBR Green I Nucleic Acid Gel Stain Molecular Probes, Invitrogen, Darmstadt, 
Germany 
Z-VAD-FMK Promega GmbH, Mannheim, Germany 
LBY135 Novartis, Basel, Switzerland 
Tigatuzumab (CS-1008) Daiichi Sankyo, Edison, NJ, USA 
DMSO Carl Roth GmbH 
TEMED Bio-Rad Laboratories GmbH, Munich, 
Germany 
Bovine serum albumin (BSA) Carl Roth GmbH 
DN/RNase-Free H2O Qiagen GmbH, Hilden, Germany 
2-Mercaptoethanol Sigma-Aldrich Chemi GmbH 
Tween® 20 Sigma-Aldrich Chemi GmbH 
propidium iodide Sigma-Aldrich Chemi GmbH 
Non-fat dry milk Bio-Rad Laboratories GmbH 
Other common chemicals (Ethidium 
Bromide (EB), Agarose, Tris, sodium 
dodecyl sulphate (SDS), methanol, 
sodium citrate, Triton X-100, etc) 
Carl Roth GmbH 
3.1.3 Media, solutions for cell culture 
Product information Manufacturers 
DMEM high Glucose (4.5 g/l) GE Healthcare, PAA Laboratories GmbH, 
Pasching, Austria 
Dulbecco's PBS Sigma-Aldrich Chemi GmbH 
RPMI medium GE Healthcare 
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Opti-MEM® I Reduced Serum 
Medium  
Gibco, Life Technologies GmbH, Darmstadt, 
Germany 
FBS Superior Biochrom AG, Berlin, Germany 
Penicilin/Streptomycin (100 ×) PAA Laboratories GmbH 
Trypsin PAA Laboratories GmbH 
Poly-L-lysine Trevigen, R&D systems GmbH, 
Wiesbaden-Nordenstadt, Germany 
3.1.4 Vector 
Vector pcDNA3.1 with neomycin resistance (Fig. 2) was purchased from 
Invitrogen. Transfected vectors contained the complete coding sequence of either of 
three different HSP27 constructs under the control of the human HSP27 promoter 
were provided by Prof. Dr. Med. Claus Schaefer (Department of Medicine II, 
Klinikum Neumarkt, Neumarkt i. d. OPf., Germany). The HSP27 constructs consisted 
either of wild-type human HSP27 (hu) or mutants with the serines 15, 78 and 82 
substituted to alanines (3A) or aspartic acids (3D). The mutant 3A represents a 
non-phosphorylatable kinase-dead form of HSP27 while 3D imitates a permanently 
phosphorylated form through insertion of the three negatively charged residues 
[154,155]. In short, the transfected plasmids/cells were labeled with ‘hu’, ‘3A’, ‘3D’, 
respectively.  
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Figure 2. Map of pcDNA 3.1 (Invitrogen
TM
 Life Technologies) 
3.1.5 Preparation of buffers, solutions, and gels  
1 mg/ml BSA (-20 °C) 
Amount Ingredients 
10 mg BSA 
10 ml ddH2O 
Hoechst 33342 (Sigma-Aldrich Chemie GmbH) 
A stock of 10 mg/ml was prepared in ddH2O and stored at room temperature (RT), 
avoiding light. 
Resolving gel solution (4 °C) 
Amount Ingredients 
400 ml ddH2O 
250 ml 1.5 M Tris pH 8.8 
10 ml 10% SDS 
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Stacking gel solution (4 °C) 
Amount Ingredients 
340 ml ddH2O 
62.5 ml 1.0 M Tris pH 6.8 
5 ml 10% SDS 
0.2 mol/l PMSF solution (-20 °C, fresh for use in max. 6 months) 
Amount Ingredients 
34.8 g PMSF 
1 ml 2-propanol 
5 g/l Aprotinin (-20 °C) 
Amount Ingredients 
5 mg Aprotinin 
1 ml ddH2O 
10 mmol/l Leupeptin hemisulfate (-20 °C) 
Amount Ingredients 
4.8 mg Leupeptin hemisulfate 
1 ml ddH2O 
Homogenization buffer (pH 7.4, 4 °C) 
Amount Ingredients 
8.55 g Sucrose 
242.2 mg Tris Base 
76 mg EGTA 
Up to 100 ml ddH2O 
H buffer: 1ml homogenization buffer+5 µl 5 g/l aprotinin+ 5 µl 10 mmol/l leupeptin 
hemisulfate+ 5 µl 0.2 mol/l PMSF + 0.7 µl 2-Mercaptoethanol 
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5 × sample loading buffer (Laemmli buffer) (-20 °C) 
Amount Ingredients 
2.13 ml 0.5 M Tris HCl pH 6.8+ 0.4% SDS 
1 g SDS 
5 ml Glycerol 
2.8 ml ddH2O 
traces bromophenol blue 
2.56 ml ß-Mercaptoethanol  
RIPA (Radio Immuno Precipitation Assay) Buffer (4 °C) 
Amount Ingredients 
5 ml 1 M Tris-Cl pH 7.4 
3 ml 5 M NaCl 
5 ml 20% NP-40 
5 ml 10% sodium deoxycholate 
0.5 ml 20% SDS 
81.5 ml ddH2O 
Additionally, ready-to-use cocktails of inhibitors containing 1 mM PMSF, 10mM NaF, 
1 mM Natrium Orthovanadate (Na3VO4), 1 x Protein Inhibitors (complete from Roche) 
were added before using. 
1 M Tris-Cl 1 L (pH 7.4 to pH 8.0) 
Amount Ingredients 
121.1 g Tris Base 
700 ml ddH2O 
70 ml Concentrated HCl (37.2% - 12.1 M) 
Directions: 
1) Mix 121.1 g of Tris Base with 700 ml of ddH2O by stirring. 
2) Add HCl in the following volumes to reach the desired pH: 
pH 7.4 = 70 ml of HCl; pH 7.6 = 60 ml of HCl; pH 8.0 = 42 ml of HCl 
3) Fine adjust to the desired pH (7.4 - 8.0) with concentrated HCl. 
4) Add ddH2O until final volume is 1 L. 
5) Autoclave to sterilize. 
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5 M NaCl (sodium chloride) 500 ml (RT) 
Amount Ingredients 
146.1 g NaCl 
450 ml ddH2O 
20% NP-40 (Nonidet P-40) 100 ml (4 °C) 
Amount Ingredients 
20 ml NP-40 
80 ml ddH2O 
10% sodium deoxycholate (Deoxycholic acid) 100 ml (RT) 
Amount Ingredients 
10 g sodium deoxycholate 
80 ml ddH2O 
20% SDS (sodium dodecyl sulfate) 100 ml (RT) 
Amount Ingredients 
20 g SDS  
80 ml ddH2O 
SDS-PAGE Electrophoresis Running Buffer (10x) 10L (RT) 
Amount Ingredients 
303 g Tris Base 
1440 g glycine 
100 g SDS 
10 L  ddH2O 
Direction: For 1x Running Buffer: 100 ml from 10x buffer plus 900 ml ddH2O. 
Transfer Buffer without SDS (10x) 10 L (RT) 
Amount Ingredients 
303 g Tris Base 
1440 g glycine 
MATERIALS AND METHODS 
- 20 - 
 
10 L  ddH2O 
1x Transfer Buffer  500 ml (RT) 
Amount Ingredients 
50 ml 10x Transfer buffer without SDS 
100 ml Methanol (final 20% methanol) 
350 ml ddH2O 
10 × TBS (concentrated TBS) 1 L (RT) 
Amount Ingredients 
24.1 g Tris Base 
80 g NaCl 
800 ml ddH2O 
Directions: Adjust pH through pure HCl and add ddH2O up to 1 L 
1x TBST 1 L (RT) 
Amount Ingredients 
100 ml TBS 10 × 
800 ml ddH2O 
1 ml Tween20 
Directions: Adjust pH to 7.6 and add ddH2O to 1 L. 
HBSS solution 1 L (4 °C) 
Amount Ingredients 
8.00 g NaCl 
0.40 g KCl 
2.38 g HEPES 
0.35 g NaHCO3 
0.06 g KH2PO4 
0.06 g Na2HPO4 
0.1 g MgSO4•7 H2O 
0.1 g MgCl2•10 H2O 
0.185 g CaCl2•2 H2O 
1 g Glucose 
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Directions: 
1) Add ddH2O to near 1 L, and adjust PH to 7.4 and the end volume to 1 L. 
2) Use 0.2 µm filter to sterilize the solution. 
Agarose gel 2% (4 °C) 
Amount Ingredients 
4 g Agarose 
200 ml ddH2O 
Directions: 
1) Use the oven to heat and mix, add 10 µl 10mg/ml EB before coagulation; 
2) Prepare gels with combs. 
PCR loading dye: 10× OG loading dye 
Amount Ingredients 
0.05 g Orange G 
1.5 g Ficol (type 400) 
1 ml 0.5 M EDTA (pH 8) 
9 ml ddH2O (sterile) 
Directions: 
1) Add Ficol to a 10~15 ml tube first then add all other ingredients inside; 
2) Mix well by vortex; 
3) Load 2~3 µl of OG for 10 µl of PCR solution; 
4) Store at RT. 
Preparing SDS-PAGE gels 10% 
Directions: 
1) Clean the plates and combs; 
2) Set up the plates on the rack; 
3) Prepare the separating gel: Pipette solutions below in order. Swirl the solution 
gently to mix thoroughly after addition of each component.  
 
MATERIALS AND METHODS 
- 22 - 
 
Components Volume 
ddH2O 2.50 mL 
40% acrylamide/bis stock 1.25 mL 
1.5 M Tris, pH 8.8 1.25 mL 
10% ammonium persulfate 50 µL 
TEMED 5 µL 
Total volume ~5 mL 
4) Prepare the stacking gel: Prepare around 1.2 mL mixture for each gel. Pipette the 
solutions carefully and swirl to mix after addition of each component. Pipette the 
gel mix between the plates up to just below the edge of the short plate quickly. 
Carefully place in the comb. 
Components Volume 
ddH2O 3.13 mL 
40% acrylamide/bis stock 0.62 mL 
1.5 M Tris, pH 8.8 1.25 mL 
10% ammonium persulfate 50 µL 
TEMED 5 µL 
Total volume ~5 mL 
5) Gel storage. The gel can be stored horizontally at 4 °C for up to 7 days. 
Gemcitabine  
Gemcitabine was dissolved at a stock concentration of 10 mM in DN/RNase-free H2O 
and stored at RT.  
LBY135  
A stock solution was made at a concentration of 50mg/ml and stored at 4 °C, 
protected from light. 
Tigatuzumab 
A stock solution was prepared at a concentration of 10 mg/ml and stored at 4 °C, 
protected from light. 
The broad-caspase inhibitor, Z-VAD-FMK 
The solution was prepared at a stock concentration of 20 mM in DMSO and stored at 
-20 °C prior to incubation. 
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3.1.6 Standard markers 
Products Manufacturers 
Precision Plus ProteinTM Standards Bio-Rad Laboratories GmbH 
O'GeneRulerTM 1 kb Plus DNA Ladder Fermentas Life Sciences, Fisher Scientific - 
Germany GmbH, Schwerte , Germany 
Low Molecular Weight DNA Ladder New England Biolabs GmbH, Frankfurt am 
Main, Germany 
3.1.7 Instruments 
Equipements Manufacturers 
Cell counting chamber (0.0025 mm2/ 0.1 
mm) 
Carl Roth GmbH 
Inverted Microscope CK2 Olympus Optical Co. (Europa) GmbH 
Vortex Mixer VM-300 NeoLab Migge, Heidelberg, Germany 
MiniSpin Eppendorf Vertrieb Deutschland 
GmbH 
Airfuge® Air-Driven Ultracentrifuge Beckman Coulter GmbH 
Sonifier Branson, Germany 
PCR gel electrophoresis chamber; power 
supply 
Bio-Rad Laboratories GmbH 
UV/Visable Spectrophotometer Ultrospec 
3100 pro 
Amersham Biosciences, Germany 
PH meter InoLab® - WTW inoLab Laborgeräte, 
Germany 
Weighing machine SCALTEL, Germany 
Mixer RCT basic KIKA® Werke, Germany 
Water bath for cell culture Medingen, Germany 
Electronic Thermometer Amarell GmbH, Kreuzwertheim, 
Germany 
Water bath for heat shock GFL®, Germany 
Tri-Carb® 2100TR Liquid Scintillation 
Counter 
PerkinElmer Life Science, Rodgau, 
Germany 
Ranin pipettes/tips for PCR/Cell culture Mettler-Toledo GmbH, Ockerweg, 
Gießen, Germany 
Cooling centrifuge Eppendorf Vertrieb Deutschland 
GmbH 
Centrifuge Hettich Rotantab, Germany 
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PCR cycler Eppendorf Vertrieb Deutschland 
GmbH 
HERA cell culture Incubator Fisher Scientific- Germany GmbH 
Laminar Hood for cell culture Fisher Scientific- Germany GmbH 
MultiDoc-It Digital Imaging System (UV 
Transilluminator) + FujiTsu Siemens 
Computer 
UVP, LLC, USA 
Milli-Q water Merck Chemicals GmbH, Schwalbach, 
Germany 
Heater (for protein denaturation) Kobe, Germany 
Western Blot shaking machine Rocky® 3D 
Western Blot Gel making unit (chamber, 
glasses, combs, etc) 
Bio-Rad Laboratories GmbH 
Electrophoresis chamber for 
immunoblotting + power supply 
Bio-Rad Laboratories GmbH 
Electrophoresis transfer unit  PeQLab Biotechnologies GmbH 
Refrigerators (+4 and -20 °C) LIEBHERR, Germany 
CytoFluor 4000 plate reader Per-Septive Biosystems, Framingham, 
MA, USA 
Zeiss Axiovert 135 TV fluorescence 
microscope 
Carl Zeiss, Jena, Germany 
fluorescence-activated cell sorter (FACS)  Accuri C6 Flow Cytometer®, BD 
Biosciences, Heidelberg, Germany 
3.1.8 Kits 
BioRad Protein assay kit (Catalog No.500-0001, Bio-Rad Laboratories) 
Kapa Taq kit for PCR (Kapa Biosystems) 
Code Description Kit Contents 
KK1015 KAPA Taq DNA 
Polymerase (500 U) 
500 units, 5 U/µL. Wild-type Taq with 10× KAPA 
Taq Buffer A, 10× KAPA Taq Buffer B (both with 
Mg2+ at a concentration of 1.5 mM), and extra 
MgCl2 (25 mM) 
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Mitochondrial membrane potential staining kit (Sigma Aldrich) 
Catalog 
Number  
Description Components 
CS0390 Mitochondria Staining Kit For 
mitochondrial potential changes 
detection 
1 mg JC-1, 1 ml DMSO, 0.1 ml 
Valinomycin Ready Made Solution 
(1 mg/ml) 
Western Blot detection kits 
Three different detection kits for immunoblotting were purchased from Thermo 
Scientific.  
Product name and Number Description 
Pierce ECL Western Blotting Substrate 
(Product # 32106) 
An entry-level ECL substrate 
SuperSignal West Pico Chemiluminescent 
Substrate (Product # 34077) 
Twice the signal duration and sensitivity 
of entry-level ECL substrates 
SuperSignal West Dura Chemiluminescent 
Substrate (Product # 34075) 
Long signal duration and high signal 
intensity 
3.2 Methods 
3.2.1 Cell culture 
Pancreatic cancer cell lines PL5 and PL11 were kindly provided by S.E. Kern (Johns 
Hopkins University, Baltimore, MD, USA). PL5 cells were also named 
Panc 04.03 (ATCC®CRL-2555TM). All other pancreatic cancer cell lines, Su86.86, 
MIA PaCa-2, AsPc1, CFPAC1, Panc1, BxPc3, Capan1, Capan2, PL3, PL45-12, PL8, 
were purchased from the European Collection of Cell Cultures (Sigma-Aldrich, 
Munich, Germany) or the American Type Culture Collection (LGC Standards, Wesel, 
Germany), respectively. Early-passage primary human pancreatic cancer cell lines 
518-665703 (short for 518), 202-587027 (202), 311-368623 (311), 520-051403 (520), 
455-903753 (455), PPC0039 were derived and propagated in our laboratory from 
surgical specimens of pancreatic adenocarcinoma from patients (Klinikum 
Grosshadern, Ludwig Maxilians University, Munich, Germany). Cells were grown 
routinely in DMEM media (PL5, PL11, Su86.86, MIA PaCa-2, CFPAC1, Panc1, 
MATERIALS AND METHODS 
- 26 - 
 
Capan1, Capan2, PL3, PL45-12, PL8 cells) or in RPMI media (AsPc1, BxPc3 cells), 
supplemented with 10% FCS, L-glutamine and 1% P/S and incubated in a 5% CO2 
humidified atmosphere. Every 2~3 days, cells were digested with trypsin. 
3.2.2 Detection of Mycoplasma contamination 
Many methods are available to detect mycoplasma, including isolation on selective 
microbiological growth media, direct or indirect fluorescent staining, the 
enzyme-linked immunosorbent assay (ELISA), autoradiography, immunostaining and 
direct or nested PCR [156]. Among all methods, PCR appears to be a fast, sensitive 
method in the laboratories, although it might give false positives or false negatives 
[157]. 
In order to obtain reliable results with a relatively high sensitivity and specificity, our 
lab has optimized this method through regular examinations under the inverted or 
fluorescence microscope and by PCR, usage of fresh cells less than two months and 
treating the contaminated cells with drugs or discarding contaminated cells 
immediately. We used one standard primer pair (Forward Primer: 5' GGG AGC AAA 
CAG GAT TAG ATA CCC T 3'; Reverse Primer: 5' TGC ACC ATC TGT CAC TCC 
GTT AAC CTC 3'; Product size: 280 bp) [158] purchased from Metabion (Metabion 
international AG, Munich, Germany) and prepared the PCR reaction solution 
according to the following recipe. 1 µl of cell culture media was regarded as the 
template, and GAPDH was used as a loading control, while 1 µl sterilized 
DN/RNase-Free H2O as the negative control and two of 1 µl formerly contaminated 
samples as the positive controls. 
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Ingredients 1× Master Mix 
10× Kapa Buffer B 7.36 µl 
dNTP (10 mM) 0.2 µl 
100% DMSO 0.2 µl 
Primer Mixture (10 mM) 0.2 µl 
Kapa Taq polymerase (1 U/µl) 0.04 µl 
Template 1 µl 
add DN/RNase-Free H2O H2O to 10 µl 
The PCR reaction procedures were as follows,  
 
3.2.3 Generation of cell clones stably overexpressing different HSP27 protein 
variant 
3.2.3.1 G418 selection test 
Cells were seeded with at 300000 cells/well in 6-well plates to make sure the 
confluence reached ~50% the next day. Cells were washed once with fresh DMEM 
medium (containing 10% FCS, 1% P/S) and cultured with G418 at concentrations of 0, 
0.1, 0.2, 0.4, 0.8, 1.6 mg/ml or 0, 0.125, 0.25, 0.5, 1.0, 2.0 mg/ml. Cells were 
examined, growth patterns recorded after 5, 10, and 15 days, and optimized cell 
concentrations (i.e. 100% cell death) used for consecutive drug selection. 
3.2.3.2 Stable transfection by PEI, Lipofectamine™ or Lipofectamine™ 2000 
Cells were cultured in 10 cm dishes to reach a confluence of 60~ 80%. On the next 
day, 2 µg transfected vector and a related volume of transfection reagent were 
incubated separately in 250 µl OptiMEM medium for 5 min. Two solutions were 
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mixed and incubated for 20 min. Cultured cells were washed once with DMEM 
medium and the above mixture was added drop-wise to the cells. 4~ 6 h later, 10 ml 
fresh DMEM medium was added to stop the transfection. 24 h later, culture medium 
was changed with fresh DMEM medium containing previously optimized 
concentrations of G418. Four weeks later, surviving clones were transferred into 
6-well plates. 
Three transfection reagents including PEI, Lipofectamine™ or Lipofectamine™ 2000 
were tested. For the generation of a control cell line, cells were transfected with 
unaltered vector pcDNA3.1 (empty vector, EV). 
3.2.3.3 Single cell dilution 
The above surviving polyclonal cells (harboring different expression levels of HSP27 
in each clone) were single-cell selected and single clones displaying high 
overexpression of HSP27 picked. Single-cell dilution was performed by cell seeding 
at concentrations of 0.2, 1, 5 cell(s)/well in 96-well plates. Two weeks later, single 
clones were labeled. Four weeks later, cells were transferred into 6-well plates for 
propagation and consecutive screening by immunoblotting. 
3.2.3.4 Screening the clones with the overexpression of HSP27 
When cells reached a confluence of around 85%, around 80% cells were harvested for 
immunoblotting to compare the expression of HSP27 among parental, EV-transfected, 
HSP27 construct-transfected clones. The clones with a high expression of HSP27 
were cultured in 10 cm dishes and frozen for further experiments. 
3.2.4 Gemcitabine metabolism 
3.2.4.1 Uptake of [
3
H] Gemcitabine 
Cells were cultured in 6-well plates to reach a confluence of around 60~70%. The 
next day, cells were washed three times with sodium-containing (+Na) and 
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sodium-free (-Na) buffer, respectively. Cells were then cultured in Incubation Buffer 
(above buffers containing 1 µM [3H] Gemcitabine) for different time points (10, 20, 
40, or 80 min and 0, 1, 2, 4, or 8 h). Afterwards cells were washed three times with 1 
ml Stop Buffer (above buffers containing 10 µM [3H] Gemcitabine). Consequently, 
buffer was discarded and 0.5 ml Trito-X-100 (1%) was added. 0.4 ml of the samples 
was collected for radioactivity detection through a Radiation Counter and 0.1 ml for 
protein measurement (Bradford method [159]). 
3.2.4.2 Immunoblotting of membrane transporters, HSP27 phosphorylation, p38 
and JNK pathways 
To detect membrane transporters, cells were either treated to dissect cytosol and 
membrane lysates or whole lysates were used. All protocols are explained in the part 
‘Immunoblotting’ (see below). 
3.2.5 Flow cytometry 
Apoptosis and cell cycle were analyzed by assessing sub-G1 events or cell cycle 
distribution using a fluorescence-activated cell sorter (FACS) (Accuri C6 Flow 
Cytometer®, BD Biosciences, Heidelberg, Germany) and CFlow Plus software (BD 
Biosciences) according to the method by Nicoletti [160]. Cells were seeded in 6-well 
plates or 12-well plates to reach a confluence of 50~60% the next day. Gemcitabine 
was then added at the end concentrations of 0, 6.25, 15 or 25 nM. After 24 and 48 h, 
the cells were split by trypsin, collected and washed with sterilized, ice-cold PBS 
once, then incubated in staining buffer containing 0.1% sodium citrate, 0.1% Triton 
X-100 and 50 µg/mL propidium iodide (PI). Sub-G1 events and cell cycle distribution 
were measured using CFlow Plus software. Specific rate of apoptosis was calculated 
as (rate sample - ratecontrol) / (1 - ratecontrol). 
3.2.6 Hoechst staining 
Cells were cultured in 6-well plates with or without sterilized slides inside. The next 
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day, cells were treated with gemcitabine at 0, 6.25, 15, 25 nM for 24, 36, or 48 h. 
Afterwards, cells were fixed with 4% paraformaldehyde in PBS for 20 min followed 
by washing with PBS twice. Fixed cells were then stained using Hoechst 33342 at 2.5 
µg/mL in PBS for 20~30 min and subsequently examined using a Zeiss Axiovert 135 
TV fluorescence microscope for morphological changes. 
3.2.7 Immunoblotting 
3.2.7.1 Lysate preparation 
Whole cell lysates 
Cells were scraped off the culture dishes/plates and centrifuged at a low speed (i.e. 
800 rpm) for 10 sec. The supernatant was discarded and cells were washed with PBS 
twice. PBS was then carefully completely removed. Cell pellets were lysed in RIPA 
buffer for 20~30 min on ice. The cell lysate was finally centrifuged at high speed (i.e. 
1000 rpm) at 4 °C for 10 min. The supernatant was stored at -80 °C as ‘whole cell 
lysate’.  
Preparation of crude membrane fraction by ultracentrifugation 
Cells were cultured in 6-well plates until a confluence of around 50~60% was reached 
and treated with a therapeutic agent(s) according to respective experiments. Cells 
were then washed with cold PBS twice and 150 µl H buffer was added. Afterwards, 
cells were collected, centrifuged at 4 °C for 2 min and the supernatant was discarded. 
150 µl H buffer was added and sonificated for 5 sec. Mixture was centrifuged for 2 
min to precipitate the nucleus. The supernatant was transferred to a microtube and 
centrifuged again using Airfuge at the highest speed. The supernatant was collect as 
the cytosolic fraction. An appropriate volume (20~30 µl) of H buffer was added and 
the membrane pellet was rinsed with a tip, resuspended and transferred as the 
membrane suspension. 
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3.2.7.2 Protein quantification 
The Bradford assay was used to measure protein concentrations of lysates [159]. First, 
the Bradford reagent was diluted fivefold in ddH2O (1 part Bradford: 4 parts ddH2O). 
Second, a serial diluted BSA solution (0.2, 0.4, 0.6, 0.8 mg/ml) was used to create a 
standard curve. Third, 1~5 µl of the protein extract was mixed with 1 ml the diluted 
reagent in a clean and dry plastic cuvette. The plate was incubated at RT for 10 min 
before the absorbance was measured at 595 nm with a spectrophotometer. The 
concentration of each sample was calculated according to the established standard 
curve. 
3.2.7.3 Immunoblotting 
Gel running  
The cell extracts were mixed with 5 × Laemmli loading buffer, ddH2O and adjusted 
with water to reach identical end concentrations. Lysates were then cooked at 95 °C 
for 10 min, spun down and loaded on precast SDS-PAGE gels (10%) using identical 
amounts (20~60 µg). Gels were run at 80 V for 30 min and then at 120 V for 30~60 
min. One lane was used for the molecular weight standard, Precision Plus ProteinTM 
All Blue Standards (6µl). 
Gel transferring 
After separation, proteins were transferred to a PVDF membrane in a transfer 
chamber. Before the transfer, the membranes are activated by isopropanol incubation 
for 10 s. After activation, the membrane was briefly washed with deionized water and 
rinsed in transfer buffer to be equilibrated. For the transfer, the PeQLab semi-dry 
transfer system was used. The transfer took place at a constant flow of 125 mA for 
45~ 60 min. 
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Blocking, incubation and detection 
Membranes were blocked for 1 h in TBS solution containing 0.1% Tween 20 (TBST) 
and 5% milk powder. Membranes were then incubated with primary antibodies in 
TBST containing 5% milk powder or 5% BSA, respectively, at 4 °C overnight, 
followed by the appropriate secondary antibody for 1 h at RT. Immunoblotting were 
developed using the ECL system according to the manufacturer’s instructions. The 
following first antibodies were used: anti- HSP27 (SPA-803, Stressgen/Enzo, Lörrach, 
Germany); anti- phospho-HSP27 (ser15, ser78, ser82) (Stressgen/Enzo) ; anti- hCNT1, 
anti- hCNT3, anti- hENT1 (kindly provided by Ralf Wimmer); anti- p38α, anti- 
phospho-p38 MAP Kinase (Thr180/Tyr182) (Santa Cruz Biotechnology, Dallas Texas 
USA); anti- SAPK/JNK, anti- phospho-SAPK/JNK (Thr183/Tyr185), anti- CASPASE 3, 
anti- CASPASE 8, anti- CASPASE 9, anti- PARP, anti- BCL-2, anti- BCL-xL, anti- 
BID, anti- BAD, anti- BAX, anti- MCL-1 (Cell Signaling Technology, Boston MA 
USA); anti- BAK, anti- FADD, anti- FLIP (Santa Cruz Biotechnology); anti- BIM 
(BD Biosciences). Anti-ß-ACTIN antibody (Sigma) served as loading control. The 
membranes were washed and stained with either anti-mouse or anti-rabbit 
HRP-conjugated antibody (GE Healthcare). Enhanced chemo-luminescence was 
elicited using ECL Western Blotting Substrate. 
3.2.8 RNA interference 
Cells were plated to reach a confluence of 40~ 60%. On the next day, cells were 
transfected using Oligofectamine (Invitrogen) and siRNA directed against HSP27 
(sense: GGACGAGCAUG-GCUACAUCTT, antisense: 
GAUGUAGCCAUGCUCGUCCTT; Qiagen) at a final concentration of 100 nM. The 
transfection proceeded for 4 h before adding serum-containing medium. HSP27 
protein depletion was quantified by immunoblotting at 24, 48, 72, 96, 120, 144, 168, 
or 192 h after transfection. Gemcitabine was added to the cells at previously 
determined time point of maximal HSP27 down-regulation, which was separately 
confirmed for each experiment. 
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3.2.9 Cell proliferation assay 
The assays were performed over a broad range of concentrations covering 100 to 0% 
cell survival. 600 to 2500 cells/well were seeded in 96-well plates to reach confluence 
on day 6. After settling, the cells were incubated with various drugs at the indicated 
concentrations. For caspase inhibition experiments, cells were pre-treated using the 
Z-VAD-FMK pan-caspase inhibitor [161] at 20 µM for 3 h and then treated with 
gemcitabine. Following incubation for 6 d, the cells were washed, lysed in 100 µl 
H2O, and 0.2% SybrGreen (Invitrogen) was added. Fluorescence was measured using 
a CytoFluor 4000 plate reader (Applied Biosystems, Darmstadt, Germany) and 
growth inhibition calculated as compared to the untreated control samples. At least 
three independent experiments were performed per agent, with each data point 
reflecting triplicate wells. 
3.2.10 Evaluation of mitochondrial membrane potential by JC-1 staining 
Cells were cultured in poly-L-Lysine-coated 6-well or 96-well plates for 24 h and then 
treated with gemcitabine at 0, 25, or 50 nM for 6 or 24 h, respectively. Next, cells 
were stained with 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazol-carbo-
cyaniniodide (JC-1) solution at a final concentration of 25 µg/ml for 30 min. Fluo-
rescence was measured employing a CytoFluor 4000 plate reader at 485 nm 
(excitation) and at 530 and 580 nm (emission). The ratio of green and red 
fluorescence signals served as surrogate readout for the mitochondrial membrane 
potential (∆ψm) independent of the mitochondrial mass; For fluorescence imaging, 
cells were grown directly on slides, treated as described above and pictures taken 
using the Zeiss Axiovert 135 TV fluorescence microscope; For FACS analysis, cells 
were harvested and analyzed using the Accuri C6 Flow Cytometer®. Qualitative and 
quantitative data were recorded through CFlow Plus software. Valinomycin or 
carbonyl cyanide 3-chlorophenylhydrazone served as negative controls. All 
experiments were performed at least in triplicate.  
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3.2.11 Experimental heat shock in combination with gemcitabine treatment 
After individual determination of the half maximal inhibitory concentration (IC50) of 
gemcitabine for each cell line, the heat-shock conditions were individually optimized 
for each cell line in regard to maximal HSP27 induction, as determined by 
immunoblotting, along with minimal toxicity, as determined by proliferation assays. 
After cell seeding and attachment, culture dishes at 60 to 70% confluence were 
wrapped with parafilm and immersed in a water bath at 41.8 or 43 °C for 15, 30, 60, 
90, 120, or 150 min, respectively. Cells subjected to 37 °C served as controls. 
Constant temperature was verified through continuous monitoring. Afterwards, the 
cells were recovered at 37 °C for 24 h and harvested for immunoblotting. In another 
set of experiments, heat-shock was performed at 41.8 °C for 0, 60, or 90 min, 
respectively, depending on the respective cell line. Afterwards, cells were incubated 
with gemcitabine at 0, 25, 50, 100, or 200 nM for 5 d. Cell survival rates were 
measured using a CytoFluor 4000 plate reader. Experiments were repeated at least in 
triplicate. 
3.2.12 Statistical analysis 
All statistical analyses were performed using IBM SPSS Statistics 21 (SPSS Inc., 
Chicago, IL, USA). Error bars represent standard error of the mean (SEM) from three 
experiments. Sensitivity studies were statistically interpreted using a paired Student’s 
t-test. P-values <0.05 were considered statistically significant. 
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4. RESULTS 
4.1 Exclusion of mycoplasma contamination 
To detect mycoplasma contamination, polymerase chain reaction (PCR) was applied. 
In a representative PCR result, our three cell lines were mycoplasma negative as 
compared to the two positive controls and one negative control (Fig. 3).  
 
Figure 3. Detection of mycoplasma contamination. A representative PCR result using two 
positive controls (+ con 1, + con 2), one negative control (- con), three pancreatic cancer cell 
lines (AsPc1, PL5, Panc1) from our group and three other cell lines (HepG2, FL/FL MEF, FL/M 
MEF) from other groups. Positive band: 280 bp; Marker: 1 kb plus.  
4.2 Negative findings in gemcitabine metabolism 
To assess whether nucleoside transport might be involved in HSP27 
overexpression-mediated gemcitabine sensitivity, we first tested the uptake of [3H] 
gemcitabine among parental PL5 cells, empty-vector PL5/EV cells and the respective 
HSP27 overexpression clones (PL5/hu16, PL5/3A6). No significant differences were 
detected (data not shown).  
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Next, we quantified the expression levels of the three major nucleoside membrane 
transporters involved in gemcitabine metabolism, namely hCNT1, hCNT3 and 
hENT1, by immunoblotting. Likewise, no significant differences were detected 
among parental PL5 cells, empty-vector PL5/EV cells and the respective HSP27 
overexpression clones (data not shown). 
4.3 Independence of p38 and JNK in HSP27-dependent gemcitabine sensitivity  
Since HSP27 was reported to be regulated through p38/JNK signaling pathway [151], 
we examined whether JNK and p38 were involved in HSP27-dependent gemcitabine 
sensitivity. We used immunoblotting to detect the expression levels of p38 and 
phospho- p38 as well as JNK and phospho-JNK. As compared to parental cells, 
HSP27-overexpressing PL5/hu18 cells displayed no detectable differences in regard 
to the expression levels of JNK and p38 upon gemcitabine treatment at 25 nM for 0, 6, 
12, 24 h (Fig. 4). In addition, no constitutive phospho-p38 or phospho-JNK 
expression was detected in any of the cell clones tested (data not shown).  
 
Figure 4. Detection of JNK and p38 during HSP27-dependent gemcitabine-induced apoptosis. 
Immunoblotting displaying time-dependent changes of JNK and p38 expressions in PL5/hu18 cells 
treated with gemcitabine at 25 nM. ß-ACTIN served as the loading control. Experiments were 
performed at least in duplicate and representative results are shown. 
4.4 Influence of HSP27 depletion on chemosensitivity in pancreatic cancer cells 
We additionally used RNA-interference in a pancreatic cancer cell line exhibiting 
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constitutively high HSP27 expression to validate the experiments applying HSP27 
overexpression and to exclude cell line-specific or methodology-dependent artefacts. 
Gemcitabine sensitivity was assessed upon siRNA-mediated HSP27 down-regulation 
in AsPC-1 cells. HSP27 protein depletion efficiency was validated by immunoblotting 
48–192 h after siRNA transfection and the time points of maximal HSP27 
down-regulation were used for gemcitabine treatment. A significantly decreased 
sensitivity of HSP27 siRNA-treated AsPC-1 cells, expressing virtually no detectable 
HSP27 protein at 120–144 h after siRNA transfection as compared to 
HSP27-expressing untreated or control-transfected cells, was observed upon treatment 
with gemcitabine at 120–144 h (Fig. 5). 
 
Figure 5. HSP27 knockdown- mediated gemcitabine sensitivity in AsPc1 cells. Left: 
Immunoblotting displaying the expression of HSP27 upon siRNA treatment from one 
representative experiment in AsPc1 cells. Right: Cell proliferation assays comparing gemcitabine 
sensitivity of untreated, control-transfected and HSP27-siRNA-transfected AsPC-1 cells. Error 
bars represent SEM of four independent experiments.  
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4.5 Mediation of HSP27-dependent gemcitabine sensitivity through early S-phase 
arrest and consequent apoptosis 
To investigate the mechanism underlying HSP27-mediated gemcitabine sensitivity, 
we applied flow cytometry to analyze cell cycle distribution and quantify the sub-G1 
cell fraction as surrogate marker for apoptosis upon treatment of cells with 
gemcitabine, comparing parental PL5 cells to their corresponding 
HSP27-overexpressing counterparts (labeled PL5/hu18). As compared to parental 
cells, PL5/hu18 cells displayed a strongly increased S-phase fraction (50%) 24 h after 
gemcitabine treatment at 15 or 25 nM (Fig. 6 A+B). While only a slightly increased 
sub-G1 fraction (~15%) was detectable at the time of S-phase arrest (Fig. 6 B), a 
strong and dose-dependent increase (~90%) was observed at 48 h in PL5/hu18 cells 
(Fig. 7 A+B). 
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Figure 6. HSP27-overexpression-mediated gemcitabine sensitivity through early S-phase arrest. 
Flow cytometry comparing cell cycle distribution upon gemcitabine treatment at 0, 15, or 25 nM 
for 24 h between parental PL5 cells and their HSP27-overexpressing counterparts PL5/hu18: 
Histograms of cell cycle distributions (A) and statistical analyses from at least three independent 
experiments (B)(Left: PL5; Right: PL5/hu18). Error bars represent SEM.  
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Figure 7. HSP27-overexpression-mediated gemcitabine sensitivity through consequent 
apoptosis. Flow cytometry comparing sub-G1 cell fractions upon gemcitabine treatment at 0, 6.25, 
15, or 25 nM for 48 h between parental PL5 cells and their HSP27-overexpressing counterparts 
PL5/hu18: Histograms of cell cycle distributions (A) and statistical analyses from at least three 
independent experiments (B). Error bars represent SEM. 
4.6 Validation of apoptosis by Hoechst staining 
Next, Apoptosis indicated by the sub-G1 cell fraction was morphologically validated 
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using nuclear staining. Consistently, increased chromatin condensation and nuclear 
fragmentation were observed in HSP27-overexpressing PL5/hu18 cells upon 
gemcitabine treatment but not in parental PL5 cells (Fig. 8 A). And the morphological 
changes were in a dose- (Fig. 8 A) and time- (Fig. 8 B) dependent manner. 
Our data thus demonstrated that HSP27-dependent gemcitabine sensitivity was 
mediated first through S-phase arrest and consequently through apoptosis. 
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Figure 8. HSP27-dependent gemcitabine sensitivity through apoptosis. Hoechst staining 
comparing morphological changes upon gemcitabine treatment at 0, 6.25, 15, or 25 nM for 0, 24, 
36 or 48 h between parental PL5 cells and their HSP27-overexpressing counterparts PL5/hu18: 
(A) Representative microscopic pictures (magnification, ×10) displaying morphological 
differences upon gemcitabine at the indicated concentrations for 24 or 48 h in PL5 and PL5/hu18 
cells. (B) Higher magnification (×100) showing typical morphological features of chromatin 
condensation and nuclear fragmentation upon gemcitabine at 0, 25 nM for the indicated time 
points in PL5/hu18 cells (arrows). 
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4.7 HSP27-dependent cleavage of PARP, CASPASE 3, CASPASE 8, CASPASE 9 
To confirm and validate HSP27-dependent induction of apoptosis upon gemcitabine 
treatment, we assessed Poly (ADP-ribose) polymerase (PARP) cleavage as a general 
apoptosis marker, followed by assessment of cleavage of initiator caspases CASPASE 
8 and CASPASE 9 and of the central effector CASPASE 3. As compared to parental 
control cells, cleavage of PARP and all three caspases upon treatment was observed 
virtually exclusively in the HSP27-overexpressing PL5/hu18 cells, but not in parental 
PL5 cells. Moreover, all four proteins were cleaved in a dose-dependent (Fig. 9 left) 
and time-dependent (Fig. 9 right) manner. 
  
Figure 9. Activation of PARP and caspases during HSP27-dependent gemcitabine-induced 
apoptosis. Immunoblotting showing cleavage of PARP, CASPASE 3, CASPASE 8 and CASPASE 9 
upon gemcitabine treatment in HSP27-overexpressing PL5/hu18 but not parental control cells in a 
dose-dependent (left) and time-dependent (right) manner. Experiments were performed at least in 
duplicate and representative results are shown. 
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4.8 Caspase inhibitor-induced abrogation of HSP27-dependent gemcitabine 
sensitivity 
To confirm caspase-dependency of HSP27-mediated gemcitabine-induced apoptosis, 
the caspase inhibitor Z-VAD-FMK [161] was utilized. Consistent with the observed 
cleavage of CASPASE 3, CASPASE 8, and CASPASE 9 upon gemcitabine treatment, 
Z-VAD-FMK at 20 µM for 3 h virtually completely reversed gemcitabine sensitivity 
specifically in HSP27-overexpressing PL5/hu18 cells at 1 or 2 nM of gemcitabine. At 
higher concentrations (4 nM), caspase-independent gemcitabine toxicity was 
additionally observed (Fig. 10).  
 
 
Figure 10. Reversal of HSP27 overexpression-mediated gemcitabine sensitivity through caspase 
inhibition. Proliferation assays displaying abrogation of HSP27-dependent gemcitabine 
sensitivity through pre-incubation with the pan-caspase inhibitor Z-VAD-FMK at 20 µM for 3 h. 
Error bars represent SEM of at least three independent experiments. 
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4.9 Identification of specific apoptotic pathways involved in HSP27-dependent 
gemcitabine sensitivity 
4.9.1 HSP27-dependent activation of BIM upon gemcitabine 
To evaluate which apoptotic molecules participated in caspase-dependent apoptosis, 
we analyzed the cellular expression of major pro- and anti-apoptotic mediators along 
the intrinsic pathway upon gemcitabine treatment at 25 nM. All three isoforms of 
pro-apoptotic BIM (BIMEL, BIML and BIMS) [162] were significantly upregulated in 
a time-dependent manner specifically in HSP27-overexpressing PL5/hu18 but not in 
parental control cells, while no discernible expression changes were detected in any 
other pro-apoptotic (BID, BAX and BAK) or anti-apoptotic protein (BCL-xL, BCL-2, 
MCL-1) (Fig. 11 A+B) tested. 
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Figure 11. Modifications of apoptosis mediators in HSP27-dependent gemcitabine sensitivity. 
(A) Immunoblotting assessing expression changes of the indicated pro- or anti-apoptotic 
molecules in parental PL5 and PL5/hu18 cells upon treatment with gemcitabine at 25 nM at the 
indicated time points. ß-ACTIN served as the loading control. (B) Immunoblotting displaying 
time-dependent BIM expression changes in PL5/hu18 cells treated with gemcitabine at 25 nM. 
ß-ACTIN served as the loading control. Experiments were performed at least in duplicate and 
representative results are shown. 
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4.9.2 HSP27-dependent mitochondrial membrane potential loss upon 
gemcitabine 
As BIM is commonly regarded as a central player in the control of 
mitochondrion-mediated apoptotic processes [163], we next applied three assays 
using JC-1 staining [164] to analyze mitochondrial membrane depolarization upon 
HSP27-dependent gemcitabine-induced apoptosis. While under normal conditions, 
the JC-1 dye concentrates due to the electrochemical potential gradient in the 
mitochondrial matrix and forms red fluorescent aggregates (JC-1 aggregates), any 
event that dissipates the mitochondrial membrane potential leads to the prevention of 
JC-1 accumulation in the mitochondria and JC-1-dispersion throughout the entire cell 
leading to a shift from red to green fluorescence (JC-1 monomers) [165]. Upon 
gemcitabine at 25 or 50 nM for 24 h, ∆ψm was quantitatively decreased in 
HSP27-overexpressing PL5/hu18 but not in parental control cells, as determined by 
JC-1 fluorescence (Fig. 12). Consistently, fluorescence imaging displayed a strong 
decrease of JC-1 aggregates in PL5/hu18 cells treated with gemcitabine at 25 nM for 
24 h (Fig. 13). Similar data were obtained using FACS analysis, in which a clear and 
dose-dependent shift from JC-1 aggregates to JC-1 monomers was detected in 
PL5/hu18 cells 24 h after treatment with gemcitabine at 15 or 25 nM (Fig. 14+15). 
This effect was completely blocked by valinomycin (data not shown) or CCCP (Fig. 
3C), both serving as negative controls.  
Taken together, these data demonstrated mitochondrion-mediated apoptosis 
specifically in PL5/hu18 cells upon treatment with gemcitabine, pointing at 
involvement of the intrinsic apoptosis pathway in HSP27-dependent gemcitabine 
sensitivity in our model.  
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Figure 12. Influence of HSP27 overexpression on mitochondrial potential upon gemcitabine 
treatment using fluorimetric measurements. Quantitative assessment of dose-dependent 
mitochondrial membrane potential (∆ψm) in PL5/hu18 as compared to parental PL5 control cells 
24 h after gemcitabine treatment by determination of fluorescence upon JC-1 staining. Error bars 
represent SEM of three independent experiments. 
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Figure 13. Influence of HSP27 overexpression on mitochondrial potential upon gemcitabine 
treatment using fluorescence imaging. Representative pictures from fluorescent imaging 
(magnification, ×10) showing JC-1 aggregates (red) and JC-1 monomers (green) in PL5/hu18 
cells 24 h after treatment with gemcitabine at 0, 25 nM. Control experiments were blocked by 
CCCP. Experiments were performed in triplicate and representative results are shown. 
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Figure 14. Influence of HSP27 overexpression on mitochondrial potential upon gemcitabine 
treatment using FACS. FACS analyses displaying representative dot blots of dose-dependent ∆ψm 
loss in PL5/hu18 cells treated with gemcitabine at 0, 15, 25 nM for 24 h (the third panel) and con-
trol experiments using CCCP block (the fourth panel). All experiments were repeated at least three 
times. 
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Figure 15. Statistical analysis of the impact of HSP27 overexpression on mitochondrial 
potential upon gemcitabine treatment using FACS. Statistical analyses of three independent 
experiments using the Student’s t-test (**p＜0.01) with error bars representing SEM. 
4.10 Heat shock-inducible sensitization of pancreatic cancer cell lines towards 
gemcitabine 
4.10.1 Heat shock treatment 
Heat-shock induces upregulation of HSP27 expression in a wide variety of cells inclu-
ding pancreatic cancer cells [122,166-169]. We therefore asked, whether heat-shock 
mediated HSP27 induction would be capable of increasing gemcitabine sensitivity in 
a similar manner as did engineered HSP27 overexpression in our model, which would 
support potential clinical implications of our study in regard to the combination of 
hyperthermia with chemotherapy for pancreatic cancer patients [170-173]. To test this 
hypothesis, a panel of established pancreatic cancer cell lines (Capan1, MIA PaCa-2, 
Panc1, PL5, PL11, Su86.86) as well as short-term propagated, early-passage primary 
human pancreatic cancer cell lines previously established by us (202, 311, 455, 518, 
520, PPC-0039) was screened for heat-shock-inducible HSP27 upregulation along 
with minimal heat-shock-induced toxicity. After identification of suitable cell lines, 
optimized heat-shock conditions in regard to temperature and duration of heat shock 
were defined. At conditions causing only minimal heat-induced toxicity (41.8 °C for 
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30 to 120 min, depending on the respective cell line), eight of twelve lines were 
HSP27-inducible (PL5, PL11, Su86.86, 202, 311, 455, 518, PPC-0039). Of these, five 
lines were picked for subsequent experiments according to their favorable growth 
characteristics in cell culture (PL5, PL11, Su86.86, 202, 518). 
Of note, due to the optimized heat shock-conditions used in our experiments, we were 
able to induce HSP27 without significant concomitant increase of HSP70 or HSP90 
expression levels in most cell lines (Fig. 16), excluding HSP70 or HSP90 as a 
predominant mechanism for the observed results. 
  
  
 
Figure 16. Mild heat shock-mediated HSP27 induction. Immunoblotting displaying the 
expression levels of HSP27, HSP70, and HSP90 in the indicated established and short-term 
propagated primary pancreatic cancer cell lines upon heat-shock at 41.8 °C for 0, 15, 30, 60, 90, 
120, or 150 min, respectively. ß-ACTIN served as loading control. 
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4.10.2 Effects of gemcitabine treatment in combination with heat-shock 
At the previously determined individual time points of maximal heat shock-mediated 
HSP27 induction (Tbl. 1), all cell lines displayed increased sensitivity towards 
gemcitabine (Fig. 17 A). These results were statistically significant for four out of the 
five cell lines tested (PL5, PL11, Su86.86, 202). Similar results were obtained when 
excluding the slight detrimental effects of mild heat-shock alone (i.e. when defining 
the surviving fraction of cells treated with heat shock but without gemcitabine as 
100%) (Fig. 17 B). Taken together, mild heat shock enhanced the sensitivity of 
multiple pancreatic cancer cell lines towards gemcitabine, independent of directly 
heat-induced detrimental effects. 
Cell type Suitable heat shock time points 
PL5 60, 90 min 
PL11 60, 90 min 
Su86.86 90, 120 min 
202 30, 60 min 
518 60, 90 min 
311 30, 60 min 
Table 1. Heat shock time points of maximal HSP27 induction. 
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Figure 17. Mild heat shock-mediated sensitization of pancreatic cancer cell lines towards 
gemcitabine. Proliferation assays comparing the sensitivity towards gemcitabine, with or without 
prior heat shock at 41.8 °C for the indicated time points of maximal HSP27 induction, including 
(A) or excluding (B) the detrimental effects of heat-shock alone. Error bars represent SEM of at 
least three independent experiments. Asterisks mark statistical significance between two samples 
using the Student’s t-test (*p＜0.05 **p＜0.01 ***p＜0.005). 
4.11 Impact of HSP27-overexpression on death receptor-targeting agents 
As we unexpectedly found HSP27-dependent gemcitabine sensitivity to be partly 
mediated through CASPASE 8, indicating involvement of the extrinsic apoptosis 
pathway (Fig. 18 A+B), we asked whether HSP27 overexpression would accordingly 
directly influence the cellular sensitivity towards drugs targeting the extrinsic death 
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receptor (DR)-pathway. To test this, parental PL5, empty-vector transfected PL5/EV 
and two HSP27-overexpressing cell clones (PL5/hu16, PL5/hu18) were treated with 
tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) 
receptor-targeting agents currently tested in clinical trials, specifically the anti-death 
receptor 5 (DR5) agonistic antibodies tigatuzumab and LBY135. As determined by 
the IC50 ratios, two independently derived HSP27-overexpressing cell clones 
(PL5/hu16, PL5/hu18) were approximately three to four-fold more sensitive towards 
these drugs than parental or empty-vector transfected (PL5/EV) control cells, 
supporting our hypothesis that overexpression of HSP27 not only modulated the 
cellular sensitivity towards gemcitabine, but also towards agents directly targeting the 
extrinsic DR pathway (Fig. 5A+B). 
 
 
Figure 18. Influence of HSP27 overexpression on the cellular sensitivity towards DR-targeting 
agents. Proliferation assays comparing the sensitivity of PL5, PL5/EV cells versus two 
independently derived HSP27-overexpressing cell clones (PL5/hu16, PL5/hu18) towards 
DR5-agonistic antibodies tigatuzumab (A), LBY135 (B), respectively at the indicated 
concentrations. Error bars represent SEM of at least three independent experiments.
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5. DISCUSSION 
5.1 Summary of the present study 
Previously, we have shown that HSP27 expression significantly correlated with better 
patient survival in pancreatic cancer in our TMA studies, suggesting that HSP27 could 
serve as a prognostic marker in this tumor type. Furthermore, exogenous 
overexpression of HSP27 in HSP27 low-expressing PL5 pancreatic cancer cells 
conferred increased sensitivity to gemcitabine. Vice versa, HSP27 high-expressing 
AsPC-1 pancreatic cancer cells exhibited a significantly increased resistance towards 
gemcitabine upon siRNA-mediated HSP27 protein depletion, additionally 
substantiating our results from the PL5 overexpression model and further excluding 
cell line-specific phenomena or methodological artefacts due to clonal variability 
[122]. 
On the basis of our previous study, the present study served to depict the underlying 
mechanism of HSP27-mediated gemcitabine sensitivity in pancreatic cancer cells. 
Here we demonstrate that gemcitabine treatment caused an early S-phase arrest 
followed by BIM-, mitochondrion- and caspase-mediated apoptosis specifically in 
HSP27-overexpressing pancreatic cancer cells. Furthermore, we were able to extend 
and generalize our data by showing that mild heat shock-mediated HSP27 induction 
increased the gemcitabine sensitivity in a panel of pancreatic cancer cell lines in a 
similar manner as did genetically engineered HSP27 overexpression. Finally, our 
study unexpectedly revealed that HSP27 overexpression sensitized pancreatic cancer 
cells not only towards gemcitabine, but also towards the DR5-targeting agonistic 
antibodies tigatuzumab [174] and LBY135 [175].  
5.1.1 HSP27-mediated gemcitabine-induced S-phase arrest and apoptosis 
The predominant cell cycle effect observed in our experiments, i.e. the early S-phase 
arrest in HSP27-overexpressing pancreatic cancer cells treated with gemcitabine, is in 
concordance with the known pharmacological mechanism of action of gemcitabine: 
The nucleoside analogue belongs to the chemotherapeutic group of antimetabolites, 
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and, after cell entry and phosphorylation, becomes incorporated into DNA. This DNA 
incorporation causes stalled replication forks during replication and consequently 
leads to an S-phase checkpoint activation followed by an S-phase arrest [176]. In our 
experiments, this S-phase arrest was subsequently followed by caspase-mediated 
apoptosis, as illustrated by the activation of the initiator caspases CASPASE 8 and 
CASPASE 9 and the executioner CASPASE 3 [177] and confirmed by the virtually 
complete abrogation of these effects by a broad caspase inhibitor [161] (Fig. 19). 
Thus, the observed gemcitabine-induced pro-apoptotic effects of HSP27 
overexpression in pancreatic cancer cells were strictly caspase-dependent in our 
experiments, whereas the anti-apoptotic properties of HSP27 in other cancers have 
been reported to be mediated partly by caspase-dependent and partly by 
caspase-independent mechanisms [89]. 
Mechanistically, HSP27-dependent gemcitabine-induced apoptosis was accompanied 
by activation of BIM (Fig. 19), a pro-apoptotic protein belonging to the BH3-only 
group of Bcl-2 family members [178], which has just recently been linked to 
gemcitabine sensitivity in pancreatic cancer [179]. The fact that BIM is tightly 
involved in mitochondrion-mediated apoptosis [163] is mechanistically substantiated 
by our data on gemcitabine-induced mitochondrial membrane potential loss in 
HSP27-overexpressing pancreatic cancer cells. Cytoskeleton remodeling represents 
one of the major functions of HSP27 besides the regulation of apoptosis [92,93]. Thus, 
it is tempting to speculate that HSP27-induced cytoskeleton dissociation of BIM and 
its consecutive mitochondrial translocation - the previously described process through 
which BIM exerts its pro-apoptotic effects [163,180]-constitutes the initiating event of 
HSP27-dependent gemcitabine-induced apoptosis. These pro-apoptotic effects of 
HSP27 overexpression probably counteract and potentially outweigh any 
anti-apoptotic properties of HSP27 under certain circumstances or in certain subsets 
of tumors. This supports our previously established hypothesis of an important 
pro-apoptotic role of HSP27 in pancreatic cancer [122], which appears mechani-
stically clearly distinguishable from the well-established anti-apoptotic properties of 
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HSP27 in a variety of other cancers [83,90]. 
 
Figure 19. A pro-apoptotic role of HSP27 in pancreatic cancer. 
5.1.2 Heat shock-enhanced gemcitabine sensitivity 
Experimental studies indicate that heat-shock induces HSP27 expression in a wide 
variety of cell types including pancreatic cancer [122,166-169]. Therefore, it appeared 
mandatory to test whether heat-shock mediated HSP27 induction would be capable of 
increasing gemcitabine sensitivity in a similar manner as did engineered HSP27 
overexpression in pancreatic cancer cells. In fact, we were able to demonstrate that 
mild experimental heat shock enhanced the sensitivity towards gemcitabine in the 
majority of cell lines from a panel of established as well as short-term propagated pri-
mary pancreatic cancer cell lines. Importantly, individual pre-optimization of each cell 
line facilitated the definition of particularly mild heat-shock conditions causing only 
minimal cellular toxicity, which helped to discriminate the heat shock-induced 
increase in cell death upon gemcitabine from potential directly heat-induced 
detrimental effects. 
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5.2 Clinical prospects about our study 
5.2.1 Hyperthermia in cancer 
5.2.1.1 Hyperthermia as cancer therapy 
Since 1968, heating was reported to be used in cancer treatment [181]. Since then, 
clinical application of hyperthermia for cancer treatment was rapidly developed. At 
present, heat can be introduced through electromagnetic field technique, ultrasound, 
or perfusion methods [182]. Clinical hyperthermia is divided into three separate 
domains: whole body hyperthermia (WBH), regional hyperthermia (RHT), and local 
hyperthermia (including superficial local and interstitial local hyperthermia) (LHT) 
[182]. Various modalities of hyperthermia are applied mainly as an addition of 
chemotherapy alone [183] or with radiation [182,184]. Of Interest, clinical trials have 
shown benefit to add hyperthermia as an effective strategy in various tumor entities 
such as soft-tissue sarcoma [185], breast cancer [186], non-small cell lung cancer 
[187], pancreatic cancer [170,172,173].  
Although hyperthermia has proven effective to enhance sensitivity towards certain 
drugs or radiation in various cancers [183,188,189], several obstacles need to be 
overcome. First, the optimum temperature and duration of hyperthermia for clinical 
purposes are not sufficiently known [190]. Second, the molecular mechanism, through 
which hyperthermia increases the cellular sensitivity towards chemotherapy or 
radiation has not yet been sufficiently clarified [183,191-193]. Third, thermotolerance 
[194] has been an obstacle for adapting hyperthermia as a standard regimen [195], and 
the mechanism remains unclear.  
5.2.1.2 Effects of hyperthermia in combination with gemcitabine in our 
experiments 
Our data showing heat shock-inducible sensitization of pancreatic cancer cell lines 
towards gemcitabine, further underscore the concept of clinical trials applying 
treatment protocols including regional hyperthermia in combination with gemcitabine 
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for pancreatic cancer patients and provide a novel molecular mechanism for the 
clinically established value of this combination [170-173], i.e. hyperthermia-mediated 
HSP27 induction and consecutive increased cellular sensitivity towards gemcitabine. 
Of note, while most studies concentrate on the role of other HSPs, particularly of 
HSP70, as critical mediators of the molecular effects observed upon hyperthermia 
[183], the effects described in our study were elicited in a HSP70- and 
HSP90-independent manner, as can be derived from the optimized heat shock 
conditions, allowing HSP27 induction without significant concomitant increases of 
HSP70 or HSP90 expression in our experiments. 
5.2.2 HSP27 as a predictive marker for gemcitabine treatment 
Pancreatic cancer is a highly aggressive cancer and is clinically characterized by early 
metastatic growth, extensive drug-resistance, and high rates of recurrence [5,6]. 
During the past ten years, numerous chemotherapeutic and molecularly targeted 
agents have been evaluated alone or in combination in clinical trials. Despite 
encouraging recent advances [15,16], gemcitabine - introduced more than 15 years 
ago - remains the standard therapeutic basis in most clinical settings [14]. Due to the 
common primary or acquired resistance of pancreatic cancer cells towards 
gemcitabine [32], predictive markers for chemotherapeutic response are urgently 
needed [196,197]. Various potentially predictive biomarkers have previously been 
reported, including carbohydrate antigen 19-9 (CA19-9) [72,73], human equilibrative 
nucleoside transporter-1 (hENT1) [60], deoxycytidine kinase (dCK) [74], 
ribonucleotide reductase subunits (RRM1 [75] and RRM2 [63], Notch3 [76], Hu 
protein antigen R (HuR) [77], microRNA expression [78] or heat shock protein 27 
(HSP27). Still, none of these markers has yet proven sufficiently robust to achieve 
clinical implementation in the gemcitabine-based treatment of pancreatic cancer. 
Particularly, the role of HSP27 as a predictive marker for gemcitabine sensitivity 
remained controversial [90,122,138]. Our study now substantiates a role for HSP27 as 
a predictive marker for gemcitabine sensitivity in pancreatic cancer.  
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5.3 Novel finding: the pro-apoptotic role of HSP27 in pancreatic cancer 
Unexpectedly, we found that gemcitabine-induced HSP27-dependent apoptosis was 
mediated partly through CASPASE 8, representing the initiator caspase upon extrinsic 
DR stimulation [198]. This indicated a potential cross-talk between the extrinsic and 
intrinsic apoptosis pathways. A highly similar extrinsic/intrinsic crosstalk, 
functionally linking BIM- and mitochondrion-dependent intrinsic apoptotic signaling 
(both observed in our experiments) to the extrinsic DR cascade, has previously been 
reported in a different experimental setting [199]. Consequently we asked, whether 
HSP27 overexpression influenced sensitivity not only towards gemcitabine but addi-
tionally towards drugs directly targeting the extrinsic DR pathway. In fact, we found 
that HSP27-overexpressing cells displayed an increased sensitivity towards the 
DR5-agonistic antibodies tigatuzumab and LBY135, thus potentially identifying a 
new predictive marker of therapeutic response towards this drug class in pancreatic 
cancer. In this context, it will be important to test in future studies, whether 
heat-shock-mediated HSP27 induction increased sensitivity not only towards 
gemcitabine, as shown here, but similarly also towards DR-targeting drugs in 
pancreatic cancer. Recent studies already support this hypothesis, reporting 
hyperthermia to enhance apoptosis induced by TRAIL or the DR4-targeting 
mapatumumab in colon cancer cells in vitro and in vivo [200,201].  
5.4 Conclusion and future prospects 
In summary, we identified and mechanistically characterized a novel link between 
HSP27 expression and gemcitabine sensitivity in pancreatic cancer cells. In contrast 
to the well-established anti-apoptotic roles of HSP27, our study revealed clearly 
distinguishable pro-apoptotic functions of HSP27 in certain subsets of cancer cells. 
This could have direct clinical implications: First, HSP27 might serve as a predictive 
marker of therapeutic response towards gemcitabine or DR-targeting drugs in 
stratifying pancreatic cancer patients for tailored drug administration. Second, our 
data further substantiate the molecular basis for clinical trials applying combinations 
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of gemcitabine and regional hyperthermia for the treatment of pancreatic cancer 
[170-173]. Likewise, the combination of hyperthermia with TRAIL-receptor targeted 
therapies appears to represent a promising avenue to be further developed in future 
studies [200,202,203].
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6. TABLES AND FIGURES 
Table 1. Heat shock time points of maximal HSP27 induction. 
Figure 1. Metabolism of gemcitabine. 
Figure 2. Map of pcDNA 3.1. 
Figure 3. Detection of mycoplasma contamination. 
Figure 4. Detection of JNK and p38 during HSP27-dependent gemcitabine-induced 
apoptosis. 
Figure 5. HSP27 knockdown- mediated gemcitabine sensitivity in AsPc1 cells. 
Figure 6. HSP27-overexpression-mediated gemcitabine sensitivity through early 
S-phase arrest. 
Figure 7. HSP27-overexpression-mediated gemcitabine sensitivity through 
consequent apoptosis. 
Figure 8. HSP27-dependent gemcitabine sensitivity through apoptosis. 
Figure 9. Activation of PARP and caspases during HSP27-dependent 
gemcitabine-induced apoptosis. 
Figure 10. Reversal of HSP27 overexpression-mediated gemcitabine sensitivity 
through caspase inhibition. 
Figure 11. Modifications of apoptosis mediators in HSP27-dependent gemcitabine 
sensitivity. 
Figure 12. Influence of HSP27 overexpression on mitochondrial potential upon 
gemcitabine treatment using fluorimetric measurements. 
Figure 13. Influence of HSP27 overexpression on mitochondrial potential upon 
gemcitabine treatment using fluorescence imaging. 
Figure 14. Influence of HSP27 overexpression on mitochondrial potential upon 
gemcitabine treatment using FACS. 
Figure 15. Statistical analysis of the impact of HSP27 overexpression on 
mitochondrial potential upon gemcitabine treatment using FACS. 
Figure 16. Mild heat shock-mediated HSP27 induction. 
Figure 17. Mild heat shock-mediated sensitization of pancreatic cancer cell lines 
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towards gemcitabine. 
Figure 18. Influence of HSP27 overexpression on the cellular sensitivity towards 
DR-targeting agents. 
Figure 19. A pro-apoptotic role of HSP27 in pancreatic cancer.
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7. ABBREVIATIONS  
Tissue-microarray, TMA; 
Carbohydrate antigen 19-9, CA19-9;  
Epidermal growth factor receptor, EGFR; 
Human epidermal growth factor receptor type 2, HER2; 
Vascular endothelial growth factor, VEGF; 
Deoxycytidine kinase, dCK; 
Ribonucleotide reductase, RR; 
Deoxyribonucleoside triphosphate, dNTP; 
Cytidine deaminase, CDA; 
5’-nucleotidase, 5’-NT; 
Deoxycytidine monophosphate deaminase, DCTD; 
Deoxycytidine triphosphate, dCTP; 
Human equilibrative nucleoside transporter, hENT;  
Human concentrative nucleoside transporter, hCNT; 
Multidrug resistance protein, MRP; 
Focal adhesion kinase, FAK; 
Hu protein antigen R, HuR; 
Heat shock protein, HSP; 
Small HSPs, sHSPs; 
Heat shock transcription factors, HSFs; 
MAPK-activated protein kinase-2, MK2; 
Protein kinase C, PKC; 
Protein kinase D, PKD; 
Apoptosis signal-regulating kinase, ASK1; 
Supramolecular vesicular aggregates, SVAs; 
Tissue microarray analyses, TMA; 
Fetal calf/bovine serum, FCS/FBS; 
Penicillin/streptomycin, P/S; 
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Dulbecco's Modified Eagle Medium, DMEM; 
Roswell Park Memorial Institute medium, RPMI; 
Radio Immuno Precipitation Assay, RIPA; 
Phosphate Buffered Saline, PBS; 
Bovine serum albumin, BSA; 
Sodium dodecylsulfate, SDS; 
Hydroxyethyl piperazineethanesulfonic acid, HEPES; 
Ethidium Bromide, EB; 
Dimethyl sulfoxide, DMSO; 
Mitochondrial membrane potential, ∆ψm;  
5, 5’, 6, 6’-tetrachloro-1, 1’, 3, 3’-tetraethyl-benzimidazolocarbocyanine iodide, JC-1; 
Carbonyl cyanide 3-chlorophenylhydrazone, CCCP; 
Tetramethylethylenediamine, TEMED; 
Polyvinylidene Difluoride, PVDF; 
Phenylmethanesulfonyl fluoride, PMSF; 
Ethylene glycol tetraacetic acid, EGTA; 
Ethylenediaminetetraacetic acid, EDTA; 
Fluorescence-activated cell sorting, FACS; 
Polymerase chain reaction, PCR; 
Room temperature, RT; 
Propidium iodide, PI; 
Round per minute, RPM; 
Enzyme-linked immunosorbent assay, ELISA; 
Polyethylenimine, PEI; 
Poly (ADP-ribose) polymerase, PARP;  
Tumor necrosis factor (TNF)-related apoptosis inducing ligand, TRAIL;  
The half maximal inhibitory concentration, IC50; 
The maximal inhibitory concentration, IC100; 
Fas-Associated protein with Death Domain, FADD; 
FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein, FLIP; 
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Poly-L-lysine, PLL; 
Standard error of the mean, SEM; 
C-Jun N-terminal kinases, JNK; 
Death receptor, DR.
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8. ZUSAMMENFASSUNG 
Das Pankreaskarzinom ist eine hochaggressive maligne Erkrankung mit limitierten 
therapeutischen Optionen, insbesondere im metastasierten Stadium. Gemcitabin stellt 
hier den therapeutischen Standard dar, allerdings existieren bislang keine belastbaren 
prädiktiven Marker, die ein Therapieansprechen vorhersagen. In Vorarbeiten konnten 
wir zeigen, daß das kleine Hitzeschockprotein 27 (HSP27) einen prognostischen und 
prädiktiven Marker im Pankreaskarzinom darstellt: So zeigte einerseits eine 
Tissue-Microarray-Analyse eine Korrelation zwischen HSP27-Expression und 
verbesserter Überlebensrate bei Pankreaskarzinompatienten. Andererseits führte die 
stabile HSP27-Überexpression in-vitro in Pankreaskarzinomzellen zu einer erhöhten 
Chemosensitivität spezifisch gegenüber Gemcitabin, nicht aber gegenüber anderen im 
Pankreaskarzinom gebräuchlichen Chemotherapeutika. 
Ziel dieser Arbeit war zum Einen die Etablierung eines RNA-Interferenz 
Modellsystems zur Validierung der im Überexpressionsmodell generierten Daten, 
zum Anderen weiterführende mechanistische Untersuchungen zur Charakterisierung 
der HSP27-abhängigen Chemosensitivierung gegenüber Gemcitabin in 
Pankreaskarzinomzellen. 
In RNA-Interferenz Modell konnte oben genannte Hypothese untermauert werden, 
indem mittels siRNA-vermittelten HSP27-Knockdowns belegt wurde, daß die 
Herabregulation von HSP27 zu einer erhöhten Gemcitabin-Resistenz in 
Pankreaskarzinomzellen führt.  
Mechanistische Untersuchungen zu Zellzyklusarrest und Apoptoseinduktion wurden 
in stabil HSP27-überexpremierenden Pankreaskarzinomzellen mittels 
Durchflußzytometrie, nukleärer Färbung, Immunoblotting, Mitochondrienfärbung und 
Proliferationsassays durchgeführt. Desweiteren wurde Hyperthermie-bedingte 
HSP27-Induktion durch zellulären Hitzeschock bei 41.8°C im Wasserbad simuliert. 
Hierdurch konnte gezeigt werden, daß Gemcitabine in stabil 
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HSP27-überexprimierenden Zellen im Vergleich zu parentalen isogenen 
Kontrollzellen einen S-Phase-Arrest, gefolgt von Apoptose, induziert. Letztere wurde 
über die sub-G1-Fraktion primär quantifiziert und durch Aktivierung von PARP, 
CASPASE 3, CASPASE 8, und CASPASE 9 charakterisiert. Die beobachteten 
Effekte waren reversibel durch chemische Caspase-Inhibition. Zusätzlich konnte in 
Gemcitabin-behandelten, stabil HSP27-überexprimierenden Zellen eine 
Hochregulation von BIM, begleitet durch einen Verlust des mitochondrialen 
Membranpotentials, beobachtet werden. 
Interessanterweise, da potentiell auch klinisch relevant, zeigten 
Pankreaskarzinomlinien, in denen HSP27 mittels Hitzeschock induziert wurde, 
ebenfalls eine Gemcitabin-Sensitivierung. Schliesslich konnte nachgewiesen werden, 
daß HSP27-Überexpression eine Sensitivierung nicht nur gegenüber Gemcitabin, 
sondern auch gegenüber direkt apoptose-induzierenden Agenzien via Death Receptor 
5 (DR5) bewirkt. Dies belegt, daß HSP27-abhängige pro-apoptotische Funktionen 
nicht nur über den intrinsischen, sondern auch über den extrinsischen 
Apoptosesignalweg vermitteln werden können. 
Zusammengefasst illustriert diese Arbeit komplementär zu vielen gut untersuchten 
anti-apoptotischen Eigenschaften von HSP27 eine neue, bislang unbekannte 
pro-apoptotische Rolle von HSP27 in Tumoren, speziell im Pankreaskarzinom, die 
sowohl über den intrinsischen als auch den extrinsischen Apoptosesignalweg 
vermittelt wird. Dies legt nahe, daß HSP27 einen prädiktiven Marker für das 
Therapieansprechen auf Gemcitabin oder direkt apoptose-induzierende Agenzien 
beim Pankreaskarzinom darstellen könnte. Desweiteren definieren diese Daten eine 
neue molekulare Grundlage für klinische Studien zur Kombination von Hyperthermie 
mit Gemcitabine für Patienten mit dieser Erkrankung. 
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